News & Updates

Initial treatment with intravenous immunoglobulin (IVIG) plus infliximab resulted in less additional therapy in multisystem inflammatory syndrome in children (MIS-C) compared with IVIG alone, according to a recent study.

A single course of teplizumab treatment can hamper the rapid metabolic decline in people at high risk of type 1 diabetes (T1D), even producing improvements in the metabolic state within 3 months after treatment, and this effect is sustained for at least 6 months, according to a study.

A small study presented at RSNA 2021 has suggested that the use of levonorgestrel-releasing intrauterine contraceptive devices (LNG-IUDs) may affect background parenchymal enhancement (BPE).

Postmenopausal women with low bone mass are encouraged to participate in bone-loading exercises and maintain adequate intake of calcium and vitamin D (CaD), while the addition of risedronate along with CaD can significantly improve BMD, particularly at the spine — such are the key messages of a recent study.

The next-generation selective Bruton tyrosine kinase inhibitor zanubrutinib appears to be safe and effective in the treatment of patients with relapsed/refractory marginal zone lymphoma, as evidenced by high rates of objective response and complete response, according to data from the phase II MAGNOLIA (BGB-3111–214) study.